Novo Nordisk
Search documents
Novo Nordisk(NVO) - 2023 Q2 - Earnings Call Transcript
2023-08-10 15:41
Novo Nordisk A/S (NVO) Q2 2023 Earnings Conference Call August 10, 2023 7:00 AM ET Company Participants Daniel Bohsen - CVP & Head, IR Lars Jorgensen - President & CEO Camilla Sylvest - EVP, Commercial Strategy & Corporate Affairs Douglas Langa - EVP, North America Operations Martin Lange - EVP, Development Karsten Knudsen - EVP & CFO Conference Call Participants Martin Parkhoi - SEB Richard Parkes - BNP Paribas Exane Emily Field - Barclays Bank Peter Verdult - Citigroup Harry Sephton - Crédit Suisse Peter ...
Novo Nordisk(NVO) - 2023 Q1 - Quarterly Report
2023-04-12 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 April 3, 2023 ________________ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Novo Allé DK- 2880, Bagsvaerd Denmark (Address of principal executive offices) ________________ Indicate by check mark whether the registrant files or will file annual reports under cover ...
Keen Vision Acquisition Corp.(KVACU) - Prospectus(update)
2023-03-21 00:37
As filed with the U.S. Securities and Exchange Commission on March 20, 2023. Registration No. 333-269659 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________ AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________ KEEN VISION ACQUISITION CORPORATION (Exact name of registrant as specified in its constitutional documents) ____________________ British Virgin Islands 6770 n/a (State or other jurisdiction of incorporation or ...
Novo Nordisk(NVO) - 2022 Q4 - Annual Report
2023-01-31 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...
Novo Nordisk(NVO) - 2022 Q4 - Annual Report
2023-01-31 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 6-K _________________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 February 1, 2023 _________________________ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) _________________________ Novo Allé DK-2880 Bagsværd Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or w ...
Novo Nordisk(NVO) - 2021 Q4 - Annual Report
2022-02-01 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...
Novo Nordisk(NVO) - 2021 Q4 - Annual Report
2022-02-01 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ _________________________ _________________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 February 2, 2022 NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) | --- | |---------------------------| | | | | | | | | | _________________________ | | | | | | | | | | | | | | | | | | | (Adress of principal executive offices ...
Novo Nordisk(NVO) - 2019 Q4 - Annual Report
2020-02-05 14:36
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...
Novo Nordisk(NVO) - 2018 Q4 - Annual Report
2019-02-04 18:30
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...